checkAd

     212  0 Kommentare Primary endpoint achieved with ziritaxestat  in NOVESA trial in systemic sclerosis patients

      

    Mechelen, Belgium; 11 September 2020, 04.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports positive topline results in the NOVESA Phase 2a clinical trial with investigational ziritaxestat (GLPG1690) in patients with diffuse cutaneous systemic sclerosis (dcSSc).

    Ziritaxestat reached the primary endpoint of the study with a statistically significant change from baseline in the modified Rodnan Skin Score (mRSS) at Week 24, of -8.3 vs -5.7 for placebo.   

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Galapagos!
    Short
    32,85€
    Basispreis
    0,37
    Ask
    × 8,09
    Hebel
    Long
    26,48€
    Basispreis
    0,38
    Ask
    × 7,88
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

      600 mg ziritaxestat,
    n=21
    placebo,
    n=12
    Mean baseline mRSS (standard deviation) 27.0 (8.8) 22.5 (6.2)
    Mean change from baseline (standard error) at Week 24, p-value1 -8.3 (1.2), p=0.0411 -5.7 (1.7)

    NOVESA is a double-blind, placebo-controlled Phase 2a proof-of-concept trial evaluating the efficacy, safety and tolerability of ziritaxestat (GLPG1690) in 33 patients with dcSSc. DcSSc is a severe autoimmune disease with one of the highest mortality rates among rheumatic diseases2 with no drugs currently approved to treat the overall disease. Systemic sclerosis (SSc) affects approximately 124,000 people3 in the US and Europe4, with a predominance of female patients (>80%).

    Patients recruited for NOVESA included mostly females (70%) around 50 years old, with a mean disease duration of 1.9 years. Most patients enrolled were on a background immunosuppressant therapy during the course of the study.

    Ziritaxestat was generally well tolerated. No deaths were reported in this study. Two patients taking ziritaxestat experienced serious adverse events versus one patient in the placebo group. Both patients in the ziritaxestat group recovered fully and are still participating in the long-term extension trial.

    94% of patients (31 of the 33) who completed the NOVESA trial continued in the long-term open label extension trial.

    “We are excited to see that after showing promising activity in the phase 2 FLORA trial in idiopathic pulmonary fibrosis, ziritaxestat achieved statistically significant improvements in mRSS in diffuse SSc, the primary endpoint in the NOVESA study. Keeping in mind that this is our first study in SSc and that the impact on skin is difficult to measure on a background treatment with immunosuppressants, we are pleased with the results reported today. We will now further analyze the NOVESA data to determine next steps in SSc, a disease with important unmet medical need,” said Dr Walid Abi-Saab, Chief Medical Officer of Galapagos.

    Seite 1 von 3


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Primary endpoint achieved with ziritaxestat  in NOVESA trial in systemic sclerosis patients    Mechelen, Belgium; 11 September 2020, 04.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) reports positive topline results in the NOVESA Phase 2a clinical trial with investigational ziritaxestat (GLPG1690) in patients with diffuse cutaneous …